. 2022 Nov 15;38(12):532–540. doi: 10.1007/s40267-022-00956-0

Table 5.

Excess myocarditis cases in younger people after receiving the second dose of an mRNA vaccine in European database analyses [2, 3, 7, 10]

Population analysed (vaccine-symptom interval)	Population subgroup	Excess cases per million doses^a
Population analysed (vaccine-symptom interval)	Population subgroup	BNT162b2	mRNA-1273
23.1 million people, 81% vaccinated by study end, in 4 Nordic countries; December 2020 to October 2021 (28d) [7]	All men	6.7	49.7
	Men aged 16–24 yrs	55.5	183.9
	Men aged 25–39 yrs	5.9	80.1
	All women	0.9	4.8
	Women aged 16–24 yrs	5.7	No data
50 million vaccinated people, equal to 88% of population aged ≥ 12 y, vs controls in France; April to October 2021 (7 d) [10]	Male adolescents aged 12–17 yrs	19	Not yet approved
	Men 18–24 aged yrs	47	170
	Women 18–24 aged yrs	6	53
European Medicines Agency (7 d)^b [2, 3]	Men 12–29 aged yrs	27	132
European Medicines Agency (28 d)^b [2, 3]	Men 16–24 aged yrs	56	188

BNT162b2 Pfizer BioNTech BNT162b2 COVID-19 vaccine, mRNA-1273 Moderna mRNA-1273 COVID-19 vaccine

^aExtrapolated from cases per 10,000 or 100,000 doses

^bStudy details not reported